Cargando…

Pegylated liposomal doxorubicin in ovarian cancer

Pegylated liposomal doxorubicin is a formulation of doxorubicin in which the molecule itself is packaged in a liposome made of various lipids with an outer coating of polyethylene glycol. Liposomal technology is being used in increasing amounts in the therapy of a variety of cancers, including ovari...

Descripción completa

Detalles Bibliográficos
Autores principales: Green, Andrew E, Rose, Peter G
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2426807/
https://www.ncbi.nlm.nih.gov/pubmed/17717964
_version_ 1782156298641473536
author Green, Andrew E
Rose, Peter G
author_facet Green, Andrew E
Rose, Peter G
author_sort Green, Andrew E
collection PubMed
description Pegylated liposomal doxorubicin is a formulation of doxorubicin in which the molecule itself is packaged in a liposome made of various lipids with an outer coating of polyethylene glycol. Liposomal technology is being used in increasing amounts in the therapy of a variety of cancers, including ovarian cancers. This article reviews the mechanistic actions of this formulation, the Phase II and Phase III data that helped define the role of pegylated liposomal doxorubicin in recurrent ovarian cancer, as well as a discussion of some of the side-effects and their management.
format Text
id pubmed-2426807
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-24268072008-06-20 Pegylated liposomal doxorubicin in ovarian cancer Green, Andrew E Rose, Peter G Int J Nanomedicine Review Pegylated liposomal doxorubicin is a formulation of doxorubicin in which the molecule itself is packaged in a liposome made of various lipids with an outer coating of polyethylene glycol. Liposomal technology is being used in increasing amounts in the therapy of a variety of cancers, including ovarian cancers. This article reviews the mechanistic actions of this formulation, the Phase II and Phase III data that helped define the role of pegylated liposomal doxorubicin in recurrent ovarian cancer, as well as a discussion of some of the side-effects and their management. Dove Medical Press 2006-09 /pmc/articles/PMC2426807/ /pubmed/17717964 Text en © 2006 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Green, Andrew E
Rose, Peter G
Pegylated liposomal doxorubicin in ovarian cancer
title Pegylated liposomal doxorubicin in ovarian cancer
title_full Pegylated liposomal doxorubicin in ovarian cancer
title_fullStr Pegylated liposomal doxorubicin in ovarian cancer
title_full_unstemmed Pegylated liposomal doxorubicin in ovarian cancer
title_short Pegylated liposomal doxorubicin in ovarian cancer
title_sort pegylated liposomal doxorubicin in ovarian cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2426807/
https://www.ncbi.nlm.nih.gov/pubmed/17717964
work_keys_str_mv AT greenandrewe pegylatedliposomaldoxorubicininovariancancer
AT rosepeterg pegylatedliposomaldoxorubicininovariancancer